# Jin‐Yuan Shih

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jin-yuan-shih/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,570 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 65 |
| i10-index | 210 |
| Last Known Institution | National Taiwan University Hospital |
| OpenAlex ID | https://openalex.org/A5048965137 |
| ORCID iD | 0000-0002-2854-5067 |
| Works | 479 |

## Researcher papers

Showing 12 of 21.

- [<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib](https://scholariq.org/papers/i-met-i-amplification-occurs-with-or-without-i-t790m-i-mutations-in-i-egfr-i/)
- [Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer](https://scholariq.org/papers/management-of-acquired-resistance-to-egfr-tki-targeted-therapy-in-advanced-non/)
- [Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of <i>TWIST</i> Gene Expression](https://scholariq.org/papers/epidermal-growth-factor-receptor-cooperates-with-signal-transducer-and-activator/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Pretreatment Epidermal Growth Factor Receptor ( <i>EGFR</i> ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pretreatment-epidermal-growth-factor-receptor-i-egfr-i-t790m-mutation-predicts/)
- [Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer](https://scholariq.org/papers/effectiveness-of-tyrosine-kinase-inhibitors-on-uncommon-epidermal-growth-factor/)
- [Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study](https://scholariq.org/papers/amivantamab-plus-chemotherapy-with-and-without-lazertinib-in-egfr-mutant/)
- [Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial](https://scholariq.org/papers/afatinib-for-patients-with-lung-adenocarcinoma-and-epidermal-growth-factor/)
- [Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry](https://scholariq.org/papers/targeting-ret-in-patients-with-i-ret-i-rearranged-lung-cancers-results-from-the/)
- [The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells](https://scholariq.org/papers/the-vegf-c-flt-4-axis-promotes-invasion-and-metastasis-of-cancer-cells/)
- [Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response](https://scholariq.org/papers/lung-cancer-with-epidermal-growth-factor-receptor-exon-20-mutations-is/)
- [The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients](https://scholariq.org/papers/the-mechanism-of-acquired-resistance-to-irreversible-egfr-tyrosine-kinase/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)

## Researcher university

- [National Taiwan University Hospital](https://scholariq.org/institutions/national-taiwan-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.